首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷 CT/MRI/X光

市場調查報告書

商品編碼

1622680

全球單光子發射電腦斷層掃瞄 (SPECT) 市場規模（按產品、應用、最終用戶、地區、範圍和預測）

Global Single-Photon Emission Computed Tomography (SPECT) Market Size By Product (Standalone SPECT, Hybrid SPECT), By Application (Cardiology, Oncology), By ENd-User (Hospitals, Diagnostic Imaging Centers), By Geographic Scope And Forecast

出版日期: 2024年07月16日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

單光子發射電腦斷層掃瞄 (SPECT) 的市場規模與預測

單光子發射電腦斷層掃瞄 (SPECT) 市場規模預計在 2024 年達到 18.8 億美元，到 2031 年將達到 31.5 億美元，2024 年至 2031 年的複合年增長率為 6.70%。由於單光子發射電腦斷層掃瞄（SPECT）技術的發展以及全球心臟病和癌症發生率的上升，單光子發射電腦斷層掃瞄（SPECT）市場正在擴大。此外，對現代診斷設施的投資不斷增加以及人們對診斷認識的不斷提高正在支持 SPECT 行業的發展。全球單光子發射電腦斷層掃瞄 (SPECT) 市場報告對市場進行了全面的評估。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

全球單光子發射電腦斷層掃瞄 (SPECT) 市場的定義

單光子發射電腦斷層掃瞄 (SPECT) 影像測試可以顯示血液如何流向各個器官和組織。它用於識別心血管疾病、癌症、神經系統疾病、中風、癲癇、應力性骨折、感染、脊椎腫瘤等。核子醫學影像使用放射性示蹤劑和電腦斷層掃瞄 (CT) 進行診斷。放射性標記的示蹤劑發射出的伽瑪射線可被 CT 掃瞄儀偵測到，使醫療專業人員能夠研究組織和器官的血流情況。電腦收集伽馬輻射發射的數據並將其顯示在 CT 掃瞄上。使用這些橫截面積可以三維顯示大腦和其他器官。

SPECT 使用鎝-99m、鉈-201、草酸-123、氟-18 和氙-133 等放射性同位素。透過 SPECT 掃瞄可以檢測到流經腦部和脊椎動脈和靜脈的血流。研究表明，SPECT 可以比 MRI 或 CT 掃瞄更準確地提供腦損傷影像，因為它可以用於識別受影響區域的血流減少。透過心臟 SPECT 掃瞄檢查心臟的血流。心臟中血流不足的區域呈現深色，而血流正常的區域呈現淺色。此外，它還用於診斷未被發現的骨折，例如應力性骨折和脛骨夾板。

全球單光子發射電腦斷層掃瞄 (SPECT) 市場概覽

由於惡性腫瘤、心血管疾病等嚴重疾病的患者數量不斷增加，市場規模不斷擴大。市場主要受快速成長的醫療保健產業所推動。由於人口老化和久坐生活方式導致的疾病增加，預計市場將會擴大。此外，SPECT 機器診斷能力的發展在很大程度上受到雙模態和器官特定系統的日益使用的推動。推動市場擴張的另一個因素是冠狀動脈疾病的增加。目前，對混合 SPECT 成像系統的需求日益增長。推動市場成長的另外兩個因素是放射性藥物生產研究的擴大以及公眾對該測試類型相對於其他成像技術的多種優勢的認識的提高。新型放射性示蹤劑的開發和系統設計的持續技術改進正在進一步推動市場擴張。鎵-67是腫瘤診斷和分期的黃金標準。 Ga-67 SPECT/CT 混合影像可以準確識別淋巴瘤病變。

Ga-67 是一種常用的發炎成像劑，因為它能夠作為金屬-轉鐵蛋白複合物特異性地集中在發炎組織中，然後進一步與轉鐵蛋白受體結合。許多市場參與者提供檸檬酸鎵（GA-67），包括 Lantheus Medical Imaging 和 Mallinckrodt Nuclear。因此，預計市場將在預測期內迅速擴張，不僅由於鎵-67 的益處而且由於各種癌症和骨病發病率的上升而呈現出商業潛力。診斷影像設備需要分子同位素，然而，預計預測期內供應和可用性有限將限制全球 SPECT 市場的擴張。例如，鎝和鉬是心臟病學中許多 SPECT 程序中使用的兩種化學元素，過去幾年來多次出現供應短缺。

影響分子同位素供應的另一個因素是，出於安全考慮，一些地區無限期關閉供應同位素的核反應器。產品召回也是困擾全球 SPECT 市場的因素。 SPECT 設備應用於心血管疾病、癌症和腦功能障礙等病變、疾病和器官功能障礙，對重新分期、診斷、分期和追蹤產生不利影響。由於產品召回和 SPECT 設備的負面影響，全球 SPECT 市場面臨增加收入的問題。

概述
北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 其他亞太地區
拉丁美洲
- 巴西
- 阿根廷
- 其他拉丁美洲國家
中東和非洲
- 阿拉伯聯合大公國
- 沙烏地阿拉伯
- 南非
- 其他中東和非洲地區

第 9 章。

概述
各公司的市場排名
主要發展策略

第十章公司簡介

GE Healthcare
Philips Healthcare
Siemens Healthineers
Bruker
Toshiba Medical（Canon）
Digirad Corporation
Esaote
Invicro
LambdaSpect
Mediso Medical Imaging Systems

第 11 章重大進展

產品發佈/開發
合併和收購
業務擴展
夥伴關係和合作關係

第 12 章附錄

相關研究

簡介目錄

Product Code: 20926

Single-Photon Emission Computed Tomography (SPECT) Market Size And Forecast

Single-Photon Emission Computed Tomography (SPECT) Market size was valued at USD 1.88 Billion in 2024 and is projected to reach USD 3.15 Billion by 2031, growing at a CAGR of 6.70% from 2024 to 2031. The Single-Photon Emission Computed Tomography (SPECT) Market is expanding as a result of developments in SPECT technology as well as the rising incidence of cardiac and cancer disorders worldwide. Furthermore, increased investment in modern diagnostic facilities and rising knowledge among people regarding diagnosis are supporting the growth of the SPECT Industry. The Global Single-Photon Emission Computed Tomography (SPECT) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Single-Photon Emission Computed Tomography (SPECT) Market Definition

An imaging examination called a single photon emission computed tomography (SPECT) reveals how blood flows to various organs and tissues. It is utilized to identify cardiovascular problems, cancer, and neurological conditions as well as strokes, seizures, stress fractures, infections, and spinal tumours. A radioactive tracer and computed tomography (CT) are used in a nuclear imaging scan to provide a diagnosis. The radiolabeled tracer allows medical professionals to examine how blood flows to tissues and organs by emitting gamma rays that the CT scanner can detect. Computers gather data from the gamma-ray emissions, which are then shown on the CT cross-sections. The brain and other organs are shown in three dimensions using these cross-sections.

In the SPECT, radioisotopes including technetium-99m, thallium-201, odine-123, fluorine-18, and xenon-133 are used. Blood flow via arteries and veins in the brain and spine can be detected with a SPECT scan. Studies have demonstrated that because it is utilized to identify decreased blood flow to affected regions, it may provide more accurate findings for brain injury than MRI or CT scanning. The blood flow through the heart is examined using cardiac SPECT scans; regions of the heart with inadequate blood flow will look dark, while parts with normal blood flow will appear bright. Furthermore, it is used to diagnose undetected bone fractures, such as stress fractures and shin splints.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Single-Photon Emission Computed Tomography (SPECT) Market Overview

The market is growing because of the increase in individuals suffering from malignancies, cardiovascular diseases, and other critical ailments. The market is primarily driven by the quickly growing healthcare industry. The market is expected to expand because of ageing populations and the prevalence of ailments brought on by a sedentary lifestyle. The development of SPECT equipment's diagnostic capabilities has also been considerably aided by the rising usage of dual-modality and organ-specific systems throughout time. Another element driving market expansion is the rise in coronary artery diseases. The need for hybrid SPECT imaging systems is currently increasing. Two other factors that encourage expansion are expanding research into the production of radiopharmaceuticals and increasing public knowledge of the multiple benefits that the testing type has over other imaging techniques. The development of new radiotracers and ongoing technological improvements in system design further boost market expansion. Gallium-67 is the gold standard for tumour diagnosis and staging. Using Ga-67 SPECT/CT in hybrid imaging, lymphoma lesions may be accurately identified.

Ga-67 is a commonly used agent for the imaging of inflammation because of its ability to concentrate not specifically in inflamed tissues as a metal-transferrin complex, followed by further binding to transferrin receptors. A number of market participants, including Lantheus Medical Imaging and Mallinckrodt Nuclear, provides gallium citrate GA-67. Consequently, it is projected that the market would expand rapidly during the forecast period and present business possibilities as a result of the rising frequency of different cancers and bone conditions as well as the benefits of gallium-67. Molecular isotopes are required for diagnostic imaging equipment, however, throughout the anticipated period, a shortage of supply and insufficient availability of these isotopes is predicted to restrain the expansion of the global SPECT market. As an example, there have been multiple supply shortages for the two chemical elements technetium and molybdenum during the past few years, which are often utilized in a significant number of SPECT procedures in cardiology.

An additional factor that has had an impact on the supply of molecular isotopes is the fact that the reactors that provided the isotopes were indefinitely shut down in some regions owing to safety-related concerns. Recalls of products are another factor that is hurting the global market for SPECT. The application of SPECT equipment for lesions, illnesses, and organ dysfunctions, such as cardiovascular disease, cancer, and brain dysfunction, has adverse effects on restaging, diagnosis, staging, and follow-up. The global market for SPECT devices is having problems increasing its revenue because of product recalls and the negative impacts of SPECT devices.

Global Single-Photon Emission Computed Tomography (SPECT) Market Segmentation Analysis

The Global Single-Photon Emission Computed Tomography (SPECT) Market is segmented on the basis of Product, Application, End-User, And Geography.

Single-Photon Emission Computed Tomography (SPECT) Market, By Product

Standalone SPECT
Hybrid SPECT

Based on Product, the market is bifurcated into Standalone SPECT and Hybrid SPECT. The Standalone SPECT technology segment accounted for the largest market share in 2022 and is projected to grow at a significant CAGR during the forecast period. The segment's expansion is driven by cancer and heart divisions' increasing use of Standalone SPECT. Gamma ray-based nuclear medicine imaging systems are a type of standalone SPECT. The device can produce high-quality full-body tomographic pictures in real time and detects the gamma-ray emissions from an injected radioisotope to provide images for diagnosis and illness management.

Single-Photon Emission Computed Tomography (SPECT) Market, By Application

Cardiology
Oncology
General Imaging
Neurology
Other

Based on Application, the market is bifurcated into Cardiology, Oncology, General Imaging, Neurology, and Other. The segment cardiology accounted for the largest market share in 2022 and is projected to grow at the highest CAGR during the forecast period. Cardiologists use SPECT to see the different parts of the heart's blood flow. By administering a radioactive tracer that has been tagged with gamma cameras, doctors can examine where and how well blood flows into and around the heart. These let doctors determine whether conditions like atherosclerosis, coronary artery disease, hypertension, valvular illnesses like mitral valve prolapse, congenital bicuspid valves caused by an infection in early childhood, etc. have negatively impacted a patient's heart. The segment is expanding as a result of the globalization of cardiovascular diseases as well as increased public knowledge of heart disease diagnostics.

Single-Photon Emission Computed Tomography (SPECT) Market, By End-User

Hospitals
Diagnostic Imaging Centers
Ambulatory Surgical Centers

Based on End-User, the market is segmented into hospitals, diagnostic imaging centers, and ambulatory surgical centers. Hospitals segment accounted for the largest market share in 2022 and is projected to grow at the highest CAGR during the forecast period. The market is expected to expand as a result of ageing populations and the prevalence of ailments brought on by a sedentary lifestyle. The development of SPECT equipment's diagnostic capabilities has also been considerably aided by the rising usage of dual-modality and organ-specific systems throughout time.

Single-Photon Emission Computed Tomography (SPECT) Market, By Geography

North America
Europe
Asia Pacific
Rest of the world

Based on regional analysis, the Global Single-Photon Emission Computed Tomography (SPECT) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share and is projected to grow at a significant CAGR during the forecast period. The region's big ageing population, high prevalence of cancer cases, and high number of cardiac patients are all driving the growth of the SPECT market there.

Key Players

The "Global Single-Photon Emission Computed Tomography (SPECT) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Siemens Healthineers, Bruker, Toshiba Medical (Canon), Digirad Corporation, Esaote, Invicro, GE Healthcare, Philips Healthcare, LambdaSpect, Mediso Medical Imaging Systems, MR Solutions, TriFoil Imaging, among others.
This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

In March 2022, Two radiopharmaceuticals in development by GE Healthcare are one for Positron Emission Tomography (PET) and the other is for Single-Photon Release Calculated Tomography imaging. A PET radiopharmaceutical imaging intermediary that intends to help in the assessment of adult patients with purported Parkinsonian disorders, provide research, and enhance patient maintenance was recently announced by the business as having its first patient treated in Phase III clinical study.
In June 2021, Noria Therapeutics Inc. and PSMA Therapeutics Inc. have entered into a contract with Bayer to be acquired. Through this deal, Bayer will acquire the sole rights to a small molecule targeted at prostate-specific membrane antigen (PSMA) and a differentiated alpha radionuclide investigational drug based on actinium-225.
In March 2021, IBA (Ion Beam Applications SA and EURONEXT) and NorthStar Medical Radioisotopes LLC declared a partnership to expand technetium-99m (Tc-99m) availability on a worldwide scale. By working together, NorthStar and IBA may develop non-uranium-based Mo-99 for their proprietary Tc-99m Generation Systems (TCM Generation Systems), which are available to businesses outside of the US.
In November 2020, Prismatic Sensors AB, a Swedish start-up specialising on photon including detectors, was acquired by GE Healthcare, indicating the company's sustained strength in photon counting CT technology. The scientific performance for cancer, cardiology, neurology, and many other clinical CT claims may be greatly improved with this understanding.
Ace Matrix Analysis
The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as
Active, Cutting Edge, Emerging, and Innovators.
Market Attractiveness
The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Single-Photon Emission Computed Tomography (SPECT) Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
Porter's Five Forces
The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Single-Photon Emission Computed Tomography (SPECT) Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

1 INTRODUCTION OF THE GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porter's Five Force Model
4.4 Value Chain Analysis

5 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET, BY PRODUCT

5.1 Overview
5.2 Standalone SPECT
5.3 Hybrid SPECT

6 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET, BY APPLICATION

6.1 Overview
6.2 Cardiology
6.3 Oncology
6.4 General Imaging
6.5 Neurology
6.6 Other

7 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET, BY END USER

7.1 Overview
7.2 Hospitals
7.3 Diagnostic Imaging Centers
7.4 Ambulatory Surgical Centers

8 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 The U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 The U.K.
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Argentina
- 8.5.3 Rest of LATAM
8.6 Middle East and Africa
- 8.6.1 UAE
- 8.6.2 Saudi Arabia
- 8.6.3 South Africa
- 8.6.4 Rest of the Middle East and Africa

9 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 GE Healthcare
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Philips Healthcare
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Siemens Healthineers
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Bruker
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Toshiba Medical (Canon)
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Digirad Corporation
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Development
10.7 Esaote
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Invicro
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Development
10.9 LambdaSpect
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Development
10.10 Mediso Medical Imaging Systems
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Development